Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia
Envoy Medical (NASDAQ: COCH), a hearing health company, has strengthened its intellectual property portfolio with the issuance of three new patents in Australia. The patents cover key technologies including cochlear implant stimulation calibration, combination hearing aid and cochlear implant systems, and rechargeable battery systems.
The first patent (No. 2021391396) focuses on cochlear implant systems with testing circuits for current calibration. The second patent (No. 2021390456) addresses systems that optimize simultaneous operation of cochlear implants with external hearing aids. The third patent (No. 2022227534) covers systems for managing battery charging while maintaining safe thermal conditions.
Envoy Medical's technology focuses on fully implanted hearing solutions that eliminate external components and utilize the ear's natural anatomy for sound detection, differentiating it from traditional hearing aids and partially implanted systems.
Envoy Medical (NASDAQ: COCH), azienda specializzata nella salute uditiva, ha rafforzato il suo portafoglio di proprietà intellettuale con l'ottenimento di tre nuovi brevetti in Australia. I brevetti riguardano tecnologie chiave come la calibrazione della stimolazione degli impianti cocleari, i sistemi combinati di apparecchi acustici e impianti cocleari e i sistemi di batterie ricaricabili.
Il primo brevetto (n. 2021391396) si concentra su sistemi per impianti cocleari dotati di circuiti di test per la calibrazione della corrente. Il secondo brevetto (n. 2021390456) riguarda sistemi che ottimizzano il funzionamento simultaneo di impianti cocleari con apparecchi acustici esterni. Il terzo brevetto (n. 2022227534) copre sistemi per la gestione della ricarica delle batterie mantenendo condizioni termiche sicure.
La tecnologia di Envoy Medical si focalizza su soluzioni uditive completamente impiantate che eliminano componenti esterni e sfruttano l'anatomia naturale dell'orecchio per la rilevazione del suono, distinguendosi dagli apparecchi acustici tradizionali e dai sistemi parzialmente impiantati.
Envoy Medical (NASDAQ: COCH), una empresa dedicada a la salud auditiva, ha fortalecido su cartera de propiedad intelectual con la concesión de tres nuevas patentes en Australia. Las patentes cubren tecnologías clave como la calibración de la estimulación de implantes cocleares, los sistemas combinados de audífonos e implantes cocleares y los sistemas de baterías recargables.
La primera patente (n.º 2021391396) se centra en sistemas de implantes cocleares con circuitos de prueba para la calibración de corriente. La segunda patente (n.º 2021390456) aborda sistemas que optimizan la operación simultánea de implantes cocleares con audífonos externos. La tercera patente (n.º 2022227534) cubre sistemas para gestionar la carga de baterías manteniendo condiciones térmicas seguras.
La tecnología de Envoy Medical se enfoca en soluciones auditivas totalmente implantadas que eliminan componentes externos y utilizan la anatomía natural del oído para la detección del sonido, diferenciándose de los audífonos tradicionales y los sistemas parcialmente implantados.
Envoy Medical (NASDAQ: COCH)는 청각 건강 회사로서 호주에서 세 건의 새로운 특허를 획득하며 지적 재산권 포트폴리오를 강화했습니다. 이 특허들은 인공와우 자극 교정, 보청기와 인공와우 결합 시스템, 충전식 배터리 시스템 등 핵심 기술을 포함합니다.
첫 번째 특허(번호 2021391396)는 전류 교정을 위한 테스트 회로가 포함된 인공와우 시스템에 초점을 맞추고 있습니다. 두 번째 특허(번호 2021390456)는 인공와우와 외부 보청기의 동시 작동을 최적화하는 시스템을 다룹니다. 세 번째 특허(번호 2022227534)는 안전한 열 조건을 유지하며 배터리 충전을 관리하는 시스템을 포함합니다.
Envoy Medical의 기술은 외부 부품을 없애고 귀의 자연 해부학을 이용해 소리를 감지하는 완전 이식형 청각 솔루션에 중점을 두어 전통적인 보청기나 부분 이식형 시스템과 차별화됩니다.
Envoy Medical (NASDAQ : COCH), une entreprise spécialisée dans la santé auditive, a renforcé son portefeuille de propriété intellectuelle avec l'octroi de trois nouveaux brevets en Australie. Ces brevets couvrent des technologies clés telles que la calibration de la stimulation des implants cochléaires, les systèmes combinés d'aides auditives et d'implants cochléaires, ainsi que les systèmes de batteries rechargeables.
Le premier brevet (n° 2021391396) porte sur des systèmes d'implants cochléaires avec des circuits de test pour la calibration du courant. Le deuxième brevet (n° 2021390456) concerne des systèmes optimisant le fonctionnement simultané des implants cochléaires avec des aides auditives externes. Le troisième brevet (n° 2022227534) couvre des systèmes de gestion de la charge des batteries tout en maintenant des conditions thermiques sûres.
La technologie d'Envoy Medical se concentre sur des solutions auditives entièrement implantées qui éliminent les composants externes et utilisent l'anatomie naturelle de l'oreille pour la détection du son, se distinguant ainsi des aides auditives traditionnelles et des systèmes partiellement implantés.
Envoy Medical (NASDAQ: COCH), ein Unternehmen im Bereich Hörgesundheit, hat sein geistiges Eigentum mit der Erteilung von drei neuen Patenten in Australien gestärkt. Die Patente decken Schlüsseltechnologien ab, darunter Kochleaimplantat-Stimulationskalibrierung, Kombinierte Hörgeräte- und Kochleaimplantatsysteme sowie wiederaufladbare Batteriesysteme.
Das erste Patent (Nr. 2021391396) konzentriert sich auf Kochleaimplantatsysteme mit Testschaltungen zur Stromkalibrierung. Das zweite Patent (Nr. 2021390456) behandelt Systeme, die den gleichzeitigen Betrieb von Kochleaimplantaten mit externen Hörgeräten optimieren. Das dritte Patent (Nr. 2022227534) umfasst Systeme zur Verwaltung des Batterieladevorgangs unter sicheren thermischen Bedingungen.
Die Technologie von Envoy Medical fokussiert sich auf vollständig implantierte Hörlösungen, die externe Komponenten eliminieren und die natürliche Anatomie des Ohrs zur Schallwahrnehmung nutzen, wodurch sie sich von herkömmlichen Hörgeräten und teilweise implantierten Systemen unterscheiden.
- Expansion of intellectual property portfolio with three new Australian patents
- Patents cover diverse technological areas including stimulation calibration, hearing aid integration, and battery charging
- Technology differentiates from competitors by eliminating external components
- None.
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia.
The Australian Patent Office has issued the following three patents to Envoy Medical Corporation:
- Australian Patent No. 2021391396 on April 24, 2025. The title of the patent is Implantable Cochlear Implant Stimulation Calibration. This patent relates to cochlear implant systems having a testing circuit that determines an amount of current provided by a source element of the system. The source element can be adjusted to calibrate an amount of current provided by the system during stimulation.
- Australian Patent No. 2021390456, on May 8, 2025. The title of the patent is Combination Hearing Aid and Cochlear Implant System. This patent relates to cochlear implant systems that update operations to compensate for the presence of an external hearing aid to improve simultaneous operation of the cochlear implant system and the external hearing aid and prevent the hearing aid from skewing sounds perceived by a wearer.
- Australian Patent No. 2022227534, on May 22, 2025. The title of the patent is Recharge System for Implantable Battery. This patent relates to systems and methods for predicting a cumulative thermal dose associated with charging an implanted rechargeable battery and monitoring charging parameters such as temperature to minimize battery charging time while maintaining safe thermal conditions.
"These latest patent issuances continue to expand the depth and breadth of our intellectual property and reflect our commitment to advancing hearing technology that is integrated into patients' lives," said Brent Lucas, CEO of Envoy Medical. "Our team remains focused on delivering differentiated solutions that move the industry forward and are designed to meet the real-world needs of people living with hearing loss."
Envoy Medical's fully implanted technologies are designed to eliminate external components and leverage the natural anatomy of the ear for sound detection, offering a fundamentally different experience from traditional hearing aids or partially implanted systems.
For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the ability to obtain additional patents and develop future products or product improvements, the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
###
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: pcarlson@kcsa.com
SOURCE: Envoy Medical, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257287
FAQ
What new patents did Envoy Medical (NASDAQ: COCH) receive in Australia?
How do Envoy Medical's hearing solutions differ from traditional hearing aids?
What is the purpose of Envoy Medical's new battery charging patent?
How does Envoy Medical's hearing aid integration patent work?
